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background: Recent pivotal clinical trials demonstrated that clinical outcome after the NOBORI biolimus-eluting stent (BES) implantation 
was noninferior to that XIENCE/PROMUS everolimus-eluting stent (EES) implantation, whereas there is few data regarding comparison 
of clinical outcome between BES and EES in real-world clinical practice. We sought to assess clinical outcome between BES and EES in 
unselected patients.
methods: Between February 2010 and August 2012, a total of 2359 patients underwent percutaneous coronary intervention with either 
BES (n=1327) or EES (n=1032) implantation in our hospital. We assessed the cumulative 2-year incidence of major adverse cardiac 
events (MACE) defined as a composite of cardiac death, myocardial infarction, target lesion revascularization (TLR), and stent thrombosis 
between BES and EES groups.
results: The cumulative 2-year incidence of MACE was not significantly different between BES and EES groups (13.1% vs. 12.4%, 
P=0.41). The cumulative 2-year incidence of cardiac death, myocardial infarction, TLR, and stent thrombosis did not significantly differ 
between both groups (3.1% vs. 2.8%, P=0.54; 1.4% vs. 1.4%, P=0.80; 10.1% vs. 9.9%, P=0.45; 0.90% vs. 0.80%, P=0.97, respectively).
Conclusion:  Two-year clinical outcome after BES implantation is comparable to that after EES implantation in real-world clinical practice.
 
